Literature DB >> 20926570

Antibody to the E3 glycoprotein protects mice against lethal venezuelan equine encephalitis virus infection.

Michael D Parker1, Marilyn J Buckley, Vanessa R Melanson, Pamela J Glass, David Norwood, Mary Kate Hart.   

Abstract

Six monoclonal antibodies were isolated that exhibited specificity for a furin cleavage site deletion mutant (V3526) of Venezuelan equine encephalitis virus (VEEV). These antibodies comprise a single competition group and bound the E3 glycoprotein of VEEV subtype I viruses but failed to bind the E3 glycoprotein of other alphaviruses. These antibodies neutralized V3526 virus infectivity but did not neutralize the parental strain of Trinidad donkey (TrD) VEEV. However, the E3-specific antibodies did inhibit the production of virus from VEEV TrD-infected cells. In addition, passive immunization of mice demonstrated that antibody to the E3 glycoprotein provided protection against lethal VEEV TrD challenge. This is the first recognition of a protective epitope in the E3 glycoprotein. Furthermore, these results indicate that E3 plays a critical role late in the morphogenesis of progeny virus after E3 appears on the surfaces of infected cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20926570      PMCID: PMC3004303          DOI: 10.1128/JVI.01345-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  PE2 cleavage mutants of Sindbis virus: correlation between viral infectivity and pH-dependent membrane fusion activation of the spike heterodimer.

Authors:  J M Smit; W B Klimstra; K D Ryman; R Bittman; R E Johnston; J Wilschut
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  Structure of the immature dengue virus at low pH primes proteolytic maturation.

Authors:  I-Mei Yu; Wei Zhang; Heather A Holdaway; Long Li; Victor A Kostyuchenko; Paul R Chipman; Richard J Kuhn; Michael G Rossmann; Jue Chen
Journal:  Science       Date:  2008-03-28       Impact factor: 47.728

3.  Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate.

Authors:  M K Hart; K Caswell-Stephan; R Bakken; R Tammariello; W Pratt; N Davis; R E Johnston; J Smith; K Steele
Journal:  Vaccine       Date:  2000-07-01       Impact factor: 3.641

4.  Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses.

Authors:  Donald L Fine; Brian A Roberts; Max L Teehee; Sara J Terpening; Cindy L H Kelly; Janae L Raetz; Dale C Baker; Ann M Powers; Richard A Bowen
Journal:  Vaccine       Date:  2006-10-27       Impact factor: 3.641

5.  Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice.

Authors:  G V Ludwig; M J Turell; P Vogel; J P Kondig; W K Kell; J F Smith; W D Pratt
Journal:  Am J Trop Med Hyg       Date:  2001 Jan-Feb       Impact factor: 2.345

6.  Furin processing and proteolytic activation of Semliki Forest virus.

Authors:  Xinyong Zhang; Martin Fugère; Robert Day; Margaret Kielian
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

7.  Onset and duration of protective immunity to IA/IB and IE strains of Venezuelan equine encephalitis virus in vaccinated mice.

Authors:  M K Hart; C Lind; R Bakken; M Robertson; R Tammariello; G V Ludwig
Journal:  Vaccine       Date:  2001-11-12       Impact factor: 3.641

8.  Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus.

Authors:  R J Phillpotts; L D Jones; S C Howard
Journal:  Vaccine       Date:  2002-02-22       Impact factor: 3.641

9.  Venezuelan encephalitis emergence mediated by a phylogenetically predicted viral mutation.

Authors:  Michael Anishchenko; Richard A Bowen; Slobodan Paessler; Laura Austgen; Ivorlyne P Greene; Scott C Weaver
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

10.  Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models.

Authors:  William D Pratt; Nancy L Davis; Robert E Johnston; Jonathan F Smith
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

View more
  15 in total

1.  Cross-institute evaluations of inhibitor-resistant PCR reagents for direct testing of aerosol and blood samples containing biological warfare agent DNA.

Authors:  Timothy D Minogue; Phillip A Rachwal; Adrienne Trombley Hall; Jeffery W Koehler; Simon A Weller
Journal:  Appl Environ Microbiol       Date:  2013-12-13       Impact factor: 4.792

2.  Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice.

Authors:  Marcelo M Samsa; Lesley C Dupuy; Clayton W Beard; Carolyn M Six; Connie S Schmaljohn; Peter W Mason; Andrew J Geall; Jeffrey B Ulmer; Dong Yu
Journal:  Mol Ther       Date:  2019-01-07       Impact factor: 11.454

Review 3.  Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.

Authors:  Jean-Louis Excler; Julie Ake; Merlin L Robb; Jerome H Kim; Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2014-06-11

4.  Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development.

Authors:  Yiu-Wing Kam; Wendy W L Lee; Diane Simarmata; Sumitro Harjanto; Terk-Shin Teng; Hugues Tolou; Angela Chow; Raymond T P Lin; Yee-Sin Leo; Laurent Rénia; Lisa F P Ng
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

5.  Low temperature-dependent salmonid alphavirus glycoprotein processing and recombinant virus-like particle formation.

Authors:  Stefan W Metz; Femke Feenstra; Stephane Villoing; Marielle C van Hulten; Jan W van Lent; Joseph Koumans; Just M Vlak; Gorben P Pijlman
Journal:  PLoS One       Date:  2011-10-03       Impact factor: 3.240

6.  Functional processing and secretion of Chikungunya virus E1 and E2 glycoproteins in insect cells.

Authors:  Stefan W Metz; Corinne Geertsema; Byron E Martina; Paulina Andrade; Jacco G Heldens; Monique M van Oers; Rob W Goldbach; Just M Vlak; Gorben P Pijlman
Journal:  Virol J       Date:  2011-07-15       Impact factor: 4.099

7.  Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo.

Authors:  Torsten Rülker; Luzie Voß; Philippe Thullier; Lyn M O' Brien; Thibaut Pelat; Stuart D Perkins; Claudia Langermann; Thomas Schirrmann; Stefan Dübel; Hans-Jürgen Marschall; Michael Hust; Birgit Hülseweh
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

8.  Second generation inactivated eastern equine encephalitis virus vaccine candidates protect mice against a lethal aerosol challenge.

Authors:  Shelley P Honnold; Russell R Bakken; Diana Fisher; Cathleen M Lind; Jeffrey W Cohen; Lori T Eccleston; Kevin B Spurgers; Radha K Maheshwari; Pamela J Glass
Journal:  PLoS One       Date:  2014-08-12       Impact factor: 3.240

9.  Human-Like Neutralizing Antibodies Protect Mice from Aerosol Exposure with Western Equine Encephalitis Virus.

Authors:  Crystal W Burke; Jeffrey W Froude; Sebastian Miethe; Birgit Hülseweh; Michael Hust; Pamela J Glass
Journal:  Viruses       Date:  2018-03-24       Impact factor: 5.048

10.  A Multiagent Alphavirus DNA Vaccine Delivered by Intramuscular Electroporation Elicits Robust and Durable Virus-Specific Immune Responses in Mice and Rabbits and Completely Protects Mice against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenges.

Authors:  Lesley C Dupuy; Michelle J Richards; Brian D Livingston; Drew Hannaman; Connie S Schmaljohn
Journal:  J Immunol Res       Date:  2018-06-03       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.